Trial Profile
An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2019
Price :
$35
*
At a glance
- Drugs Auriclosene (Primary)
- Indications Infectious conjunctivitis
- Focus Therapeutic Use
- Sponsors Alcon
- 25 Aug 2011 Results published in Cataract & Refractive Surgery Today
- 18 May 2011 Primary endpoint 'Sustained-microbiological-response 20% greater than placebo' has not been met.
- 18 Oct 2010 Interim results (n=50) have been reported in a NovaBay media release.